Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Triquilar is a triphasic combined oral contraceptive pill developed by Bayer for the prevention of pregnancy. It contains two active ingredients: ethinyl estradiol (a synthetic estrogen) and levonorgestrel (a synthetic progestogen). As a triphasic formulation, it delivers three different dose combinations over a 21-day cycle to mimic the natural hormonal fluctuations of the menstrual cycle. The primary mechanism of action involves the suppression of gonadotropins, which inhibits ovulation. Additionally, it thickens cervical mucus to impede sperm penetration and alters the endometrium to reduce the likelihood of implantation. It is available in 21-day and 28-day (with 7 placebo tablets) regimens.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Triquilar.